AdipoGen Life Sciences GLP-1, GIP and GCG receptor agonists

The success of weight loss drugs like Wegovy and Mounjaro has invigorated obesity research and especially the pursuit of new treatments for obesity. Many of these drugs are targeting glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide (GIPR) and glucagon receptor (GCGR), as well as other hormones involved in satiety and metabolism; some are using entirely novel mechanisms.

Incretins are gut-derived hormones, members of the glucagon superfamily. There are two main incretin hormones in humans: GIP (glucose-dependent insulinotropic peptide, also known as gastric inhibitory peptide) and GLP-1 (glucagon-like peptide-1). Both hormones are secreted by endocrine cells that are located in the epithelium of the small intestine and are secreted on ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic β cells. GLP-1 and GIP also have other metabolic effects, such as reducing glucagon secretion from the pancreas, slowing down gastric emptying and promoting satiety.

AdipoGen’s range of GLP-1, GIP and GCG receptor agonists includes Liraglutide, Retatrutide, Semaglutide, Tirzapatide, Cagrillintide, DMB, Mazdutide and Survodutide. The range is distributed in Australia and New Zealand by Sapphire Bioscience.